Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease

Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2014, Pages 46-52

  Krishnaswami, Sriram ^a   Chow, Vincent ^a   Boy, Mary ^a   Wang, Cunshan ^a   Chan, Gary ^a  

^a PFIZER INC   (United States)

Author keywords

End stage renal disease; Janus kinase inhibitor; Pharmacokinetics; Renal impairment; Tofacitinib

Indexed keywords

CREATININE; TOFACITINIB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; END STAGE RENAL DISEASE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PHASE 1 CLINICAL TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH DISEASE; URINARY EXCRETION;

END-STAGE RENAL DISEASE; JANUS KINASE INHIBITOR; PHARMACOKINETICS; RENAL IMPAIRMENT; TOFACITINIB;

ADULT; AGED; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; FEMALE; HALF-LIFE; HUMANS; JANUS KINASES; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIVER; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RENAL DIALYSIS;

EID: 84893290345     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.178     Document Type: Article

References (19)

1. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7 (1):41.
2. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP- 690,550) in patients with rheumatoid arthritis receivingmethotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-570.
3. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
4. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-460.
5. Kremer JM, Li ZG, Hall S, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDS: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis. 2011;70(Suppl 3):170.
6. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-519.
7. Lee EB, Fleischmann R, Hall S, et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(Suppl 10):S1049.
8. Papp K, Menter A, Strober B, et al. Efficacy and safety of tofacitinib,an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-677.
9. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616-624.
10. Vincenti F, Tedesco SH, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12(9):2446-2455.
11. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875- 878.
12. Prakash C, Lin J, Chan G, Boy M. Metabolism, pharmacokineticsand excretion of a Janus kinase-3 inhibitor, CP-690,550, in healthy male volunteers. AAPS J. 2008;10(Suppl 1):2492A.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
14. US Dept of Health, FDA, and CDER, CBER. Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. 1998.
15. Lalonde RL, Wagner JA. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther. 2009;86(5):557-561.
16. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens. 2008;17(6):555-559.
17. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009;86(5):553-556.
18. Giacomini KM, Huang SM, Tweedie DJ, et al. Membranetransporters in drug development. Nat Rev Drug Discov. 2010;9 (3):215-236.
19. Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550,an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol. 2009;49(4):423-429.